Recurrence of post-liver transplantation Hepatitis C virus (HCV) infection is a major concern for patients and transplant physicians. The aim of this study is to analyze the risk factors for HCV recurrence, the effect of the recurrence and its management on the outcome of liver transplantation.

**Materials and Methods:**

After exclusion of the 6 months mortality, dual HCV and HCC patients, about fifty five LDLT patients were enrolled in the study and were followed up from 6 to 60 months. Demographic, preoperative, intraoperative and postoperative data were studied. HCV recurrence was defined by elevated transaminases, positive serum HCV RNA and liver biopsy findings. Univariate and multivariate analysis were done on all data to detect the favoring factors of HCV recurrence.

**Results:**

HCV recurrence occurred in 21/55 of the patients and one of them developed cirrhosis on follow up. By univariate analysis; CMV infection, mean operative time (12.490 ± 1.8052), acute cellular rejection and pulse steroids treatment were predictors of HCV recurrence (P=0.05). Multivariate analysis revealed only acute cellular rejection to be a predictor. The overall 1, 3 and 5 years' survival of all patients was 94.5%, 90.9% and 90.9% respectively, while the overall 1, 3 and 5 years' survival of patients with and without recurrence was 95.2%, 90.5% and 90.5% and 94.1%, 91.2% and 91.2% respectively.

**Conclusion:**

The occurrence of acute rejection was independent predictor of HCV recurrence post LDLT, so its prevention is required to decrease this recurrence. Similarly, prevention of CMV infection and decreasing operative time is important to decrease post-transplant HCV recurrence.

**Keywords:**

Living donor liver transplantation; Hepatitis C recurrence; Outcome post LDLT

Abbreviations:

ALT: Alanine Transaminase; AST: Aspartate Transaminase; BMI: Body Mass Index; CMV: Cytomegalovirus; Cns: Calcineurin Inhibitors; Csa: Cyclosporine; FK Or FK-506: Tacrolimus; GRWR: Graft Recipient Weight Ratio; HAI: Histological Activity Index; HCC: Hepatocellular Carcinoma; HCV: Hepatitis C Virus; HCV RNA: Hepatitis C Virus Ribonucleic Acid; HPB: Hepatopancreatobiliary; LDLT: Living Donor Liver Transplantation; LT: Liver Transplantation; MELD: Model for End Stage Liver Disease; MMF: Mycophenolate Mofetil; NLI: National Liver Institute; PCR: Polymerase Chain Reaction; RBV: Ribavirin; RT-PCR: Reverse-Transcription Polymerase Chain Reaction; SRL: Sirolimus; SVR: Sustained Virological Response; ULN: Upper Limit Normal

**Introduction**

Living related liver transplantation is a well-accepted therapeutic option for patients with end-stage liver disease caused by variable diseases like, chronic viral hepatitis (in particular hepatitis C, B virus infection), early-stage hepatocellular carcinoma, hepatoblastoma, Budd-Chiari syndrome and primary sclerosing cholangitis [1]. In Egyptian patients who undergo living-donor liver transplantation, hepatitis C virus related end-stage liver disease is the main indication for transplantation. Unfortunately, the recurrence of that infection after transplant is almost universal. It causes graft damage in most cases and is the leading cause of graft loss and the need for retransplant [2]. Recent reports show that 99% recurrent viremia and 46% clinical HCV recurrence occur after transplantation for HCV [3,4].

The risk factors responsible for disease recurrence are not well studied but many reports applied show that: Several factors (donor age, living-donor and donor-recipient matching, virologic features, acute rejection episodes, immunosuppression) have been shown to influence the progression of post-transplant liver disease [2]. Similarly, Cytomegalovirus (CMV) infection has been strongly associated with increased severity of HCV recurrence [5].

Furthermore, antiviral treatment in transplant patients is feasible and does not induce severe immunological effects, so, it is recommended in recurrent HCV to use antiviral in the form of PEG-IFN plus Ribavirin, with good SVR and survival [6].

The study aimed at analyzing the different factors responsible for HCV recurrence, the effect of the recurrence and its management on the outcome of liver transplantation.

**Materials and Methods**

After approval of Institutional Review Board (IRB), and obtaining written informed consents from both donors and recipients, we retrospectively and prospectively analyzed liver transplanted patients in the department of HPB surgery, NLI, university of Menoufia, Menoufia, Egypt, in the period from April 2003 to April 2013. During...
In the period, about 141 out of 200 patient underwent LDLT due HCV related cirrhosis. After exclusion of the 6 months mortality 53 patients, dual HCV and HCC patients 33 patients, about 55 HCV related LDLT patients were enrolled in the study and were followed up from 6 to 60 months. The following data were further analyzed:

Preoperative variables

Donor's age, gender, blood group, Body Mass Index (BMI) and donor to recipient relation. Recipients' age, gender, blood group, BMI, Child Pugh score, MELD score, antiviral treatment (PegINF/ RBV), endoscopic intervention for esophageal varices (band ligation, sclerotherapy), comorbidity (DM, HTN) and finally CMV infection (CMV IgG, IgM for both donors and recipients ), when CMV IgG was positive, prophylaxis was done using acyclovir 300 mg tid. Really the best drugs are ganciclovir (Cymevene®), and valganciclovir (Valcite®) but they are highly expensive besides their known nephrotoxicity and lethal bone marrow suppression. So acyclovir 900 mg/day for 6 months was given. All donors and recipients were CMV IgM negative before LT.

Intraoperative variables

Duration of the operation per hours, graft weight (calculated and actual intraoperative weight), calculated and actual graft recipient weight ratio (GRWR), cold ischemia time per minute, warm ischemia time per minute, blood transfusion per unit and finally plasma transfusion per unit.

Postoperative variables

Immunosuppression protocol: The standard is combined 3 drugs: Calcineurin Inhibitors (CNIs), steroids and Mycophenolate Mofetil (MMF). Tacrolimus (FK506) was prescribed at an initial dose of 0.05-0.1 mg/kg/day divided every 12 hours (9 a.m. and 9 p.m.) and adjusted over time to maintain levels of 10-15 ng/mL at 0-14 days, 6-10 ng/mL at 14-28 days, and 5-8 ng/mL thereafter. MMF was given at an oral dosage of 250-500 mg twice a day to be stopped 6 months later. The initial methylprednisolone dose is 500 mg intraoperatively with a brief taper of prednisone from 240 to 40 mg/d over 6 days followed by 5-20 mg/d maintenance treatment, with complete withdrawal at the end of 3rd month post LDLT. Cyclosporine (CsA) was used when neurotoxicity or nephrotoxicity developed with Tacrolimus. It was given at an oral dosage of 8-10mg/kg/day, where blood trough levels were maintained between 150 and 250 ng/ml in the 1st 6 months and between 100 and 150 ng/ml thereafter. When CNIs are contraindicated or their side effects halt their use, Sirolimus (SRL) was given at an initial dose of 3 mg/m2 and adjusted over time to achieve blood trough levels of approximately 5-8 ng/mL. Biopsy-proven acute rejection episodes were treated with steroid pulses (IV methylprednisolone 200 to 500 mg/d for 3 days), which were tapered over several days to the baseline dose.

Postoperative follow up protocol to detect HCV recurrence:

Follow up period from 6 months to 60 months: The follow up was done monthly during the 1st 6 months, then every 3 months till the 1st year, then every 6 months till the end of follow up (60 months).

Diagnosis of HCV recurrence by all of the following: 1- Laboratory results (elevated ALT, AST) ≥ 2-fold over the normal upper limit. 2- Positivity of serum HCV RNA by reverse-transcription polymerase chain reaction (RT-PCR) 3- Routine Core liver biopsies (The biopsy was performed with ultrasonographic guidance and a conventional automatic 16-gauge Tru-cut needle) to assess: a- Fibrosis: evaluated according to The META VIR (7) and/or Ishak (8) scores. The fibrosis score was measured from 1 to 6 (Trichrome stain was used). b- The inflammatory grading (18 points) (infiltration of the portal tract with mononuclear inflammatory cells, interface hepatitis, spotty necrosis, confluent necrosis). c- The Histological Activity Index (HAI): The sum of spotty necrosis score (from 1 to 4), a confluent necrosis score (from 0 to 6), interface hepatitis score (from 0 to 4), and a portal inflammation score (from 0 to 4). N.B. Other possible diagnoses (particularly cellular rejection) were excluded by the followings: a- Absence of endothelialitis and centrilobular tissue damage. b- Biopsies from patients with HCV infection contain macro or microvesicular steatosis, irregular limiting plates, lobular inflammations, hepatocyte necrosis and reactive changes of hepatocytes. c- Analysis of the liver biopsy by two expert pathologists to avoid inter-observer variation [7,8].

Treatment: Criteria for treatment of recurrent HCV were: staging >1 and grading >4. All treated patients received PEG-IFN-α-2b (PEG-Imtron, Schering Plough, and Kenilworth, NJ, USA) which was administered subcutaneously at a weekly dose of 1 μg/kg of body weight plus Ribavirin (Rebetol, Schering Plough, Kenilworth, NJ, USA) that was administered orally at the starting daily dose of 400-800 mg/day. Planned duration of treatment was 48 weeks. Patients who were HCV RNA-positive after 12 weeks of treatment were considered as non-responders and treatment was stopped. All patients were monitored monthly during and after therapy. Complete blood count, AST, ALT, bilirubin, creatinine and prothrombin time were checked monthly or more frequently, if needed. Serum HCV RNA levels were checked by RT-PCR before therapy, at 12 and 24 weeks, at the end of therapy (Quantitative test: HCV Monitor; sensitivity >600 UI/mL).

Statistical Analysis

All data were tabulated and processed with SPSS software (Statistical Product and Service Solutions, version 21, SPSS Inc, Chicago, IL, USA) and Windows XP (Microsoft Corporation, Redmond, Washington, USA). Qualitative data were expressed in frequency and percentage and analyzed with the chi-square test. Quantitative data were expressed as the mean and standard deviation and were compared with the t test. The previous (preoperative, intraoperative and postoperative) variables were descriptively studied. Univariate analysis and then multivariate analysis for significant predictors in univariate analysis were done to detect the relationship between the previous data and overall HCV recurrence and between recurrence variables (Occurrence of recurrence and its management) and overall survival of patients in the follow up period after LDLT. The Kaplan-Meier method was applied for survival analysis and time to event analysis and compared using log-rank tests. In all tests, a P value of <0.05 was considered significant and a P value of <0.01 was highly significant.

Results

Characteristics of the fifty five HCV patients and their donors

They were classified as 49 (89.1%) males, and 6 (19.9%) females. Their mean age was 46.3 years ± 5.07. Their donors were classified as 37 (67.3%) males and 18 (32.7%) females, their mean age was 26.8 years ± 8.03. They were classified according to Child-Pugh score into 1 (1.8%) class A, 12 (21.8%) class B, and 42 (76.4%) class C, and their mean MELD score was 17.2 ± 3.7 (47.3%) of them had co morbidity, in the form of Hypertension and DM, while the incidence of CMV infection was 23.6% in them (N.B. CMV IgG was positive in all donors and recipients, 2 patients developed CMV viremia and invasive CMV. Both had elevation of the liver enzymes, bilirubin plus GIT symptoms e.g. nausea, vomiting, colics and diarrhoea. One of them responded to 4 weeks ganciclovir IV therapy and the second unfortunately died
with graft failure 6 months postoperatively). The regimen including FK, MMF and steroids was given to 89.1% of them (2 patients were not given FK and another 4 patients were not given MMF). While the regimen including Cyclosporine, MMF and steroids was given to 36.4% (18 patients were switched from FK to cyclosporine and 2 patients were given cyclosporine from the start) and the regimen including sirolomus, MMF and steroids was given to 10.9% (5 patients were shifted from FK to sirolomus and 1 patient was switched from cyclosporine to sirolomus). Acute rejection episodes occurred in 14 (25.5%) of patients, and treated with steroid bolus Table 1.

**HCV recurrence and its management**

In our series, the recurrence of hepatitis C virus was universal in terms of viremia. The clinical recurrence of hepatitis C virus infection was found in 21(38.2%) of the 55 patients and diagnosed at a mean of 11.9 ± 5.5 months post transplantation. The mean fibrosis score of those 21 patients was F 2.24 ± 1.09 Ishak and the mean grade of inflammation was 6.86 ± 2.220. One of the recipients exhibited allograft cirrhosis. Sixteen (76.1%) of the 21 HCV patients was treated with PEG-IFN-α-2b and Ribavirin, 13 (81.3%) of the 16 patients completed the course of treatment with SVR (Table 2).

**Recipient and donor risk factors as predictors of HCV recurrence**

A- On univariate analysis, the following variable was found to be statistically highly significant predictors of recurrence: Occurrence of acute rejection episodes and administration of pulse steroid therapy (acute rejection and HCV recurrence did not occur at the same time). However, infection with CMV and mean operative time of 12.490 ± 1.8952 h were statistically significant predictors of recurrence, on the other hand there was no significant correlation between the following variables and HCV recurrence (donor and recipient age, donor and recipient gender, Child-Pugh class and MELD score, Co morbidity, immunosuppression and steroid regimen, Calculated and actual graft weight, calculated and actual GRWR, cold ischemia and warm ischemia times/ minutes and amount of blood and plasma transfusion (Tables 3 and 4).

B- On multivariate analysis by linear regression test, occurrence of acute rejection episodes and administration of pulse steroid therapy was found to be independent predictor of recurrence (Table 5).

**Outcome of patients**

The mortality of all, non-recurrent and recurrent patients were

### Table 1: Characteristics of the fifty five HCV patients and their donors.

| Donor age(years) (Mean ± SD) | 26.8 ± 8.03 |
|-----------------------------|-------------|
| Donor age(years) <31        | 36 (69.1%)  |
| >=31                        | 17 (30.9%)  |
| Recipient age(years) (Mean ± SD) | 46.3 ± 7.9 |
| Donor gender                |             |
| males                       | 37 (67.3%)  |
| females                     | 18 (32.7%)  |
| Recipient gender            |             |
| males                       | 49(89.1%)   |
| females                     | 6(19.9%)    |
| Child class                 |             |
| A                           | 1(1.8%)     |
| B                           | 12 (21.8%)  |
| C                           | 42 (76.4%)  |
| MELD score (Mean ± SD)      | 17.2 ± 3.7  |
| Co morbidity                | 26 (47.3%)  |
| CMV infection               | 13 (23.6%)  |
| Calculated GRWR (Mean ± SD) | 1.23 ± 0.23 |
| Actual GRWR (Mean ± SD)     | 1.07 ± 0.18 |
| Cold ischemia time (min) (Mean ± SD) | 69.2 ± 47.4 |
| Warm ischemia time (min) (Mean ± SD) | 47.7 ± 15.3 |
| Plasma transfusion (units) (Mean ± SD) | 5.2 ± 6.4 |
| Duration of operation (hours) (Mean ± SD) | 11.5 ± 2.7 |
| Immunosuppression and steroid regimen |             |
| FK, MMF, steroids           | 49(89.1%)   |
| Cyclosporine, MMF, steroids | 20(36.4%)   |
| sirolomus, MMF, steroids    | 6(10.9%)    |
| Acute rejection episodes    | 14 (25.5%)  |
| Rejection activity index (RAI)/9 (Mean ± SD) | (5.5 ± 1.1) |

**Table 2: HCV recurrence and its management**

| Category                                      | Recurrence No( % ) | p-value |
|-----------------------------------------------|--------------------|---------|
| Number of patients                            | 21/55 (38.2%)      | > 0.05  |
| Donor age(years) <31                         | 16/38 (42.1%)      | > 0.05  |
| >=31                                         | 5/17(29.4%)        | > 0.05  |
| Recipient gender - Male                       | 20/ 49 (40.8%)     | > 0.05  |
| - Female                                      | 1/ 6 (16.7%)       | > 0.05  |
| Child class A                                 | 1/1(100.0%)        | > 0.05  |
| B                                             | 8/12 (33.3%)       | > 0.05  |
| C                                             | 16/42 (38.1%)      | > 0.05  |
| Co morbidity - No                             | 11/29 (37.9%)      | > 0.05  |
| - Yes                                         | 10/26 (38.4%)      | > 0.05  |
| CMV infection No                              | 13/42 (31%)        | 0.047   |
| Yes                                          | 8/13 (61.5%)       |         |
| Immunosuppression and steroid regimen FK, MMF, steroids | 17/49(34.7%)    | > 0.05  |
| Cyclosporine, MMF, steroids                   | 8/20 (40.0%)       | > 0.05  |
| Sirolomus, MMF, steroids                      | 3/6 (50%)          | > 0.05  |
| Acute rejection episodes No                   | 9/41 (22.0%)       | 0.000   |
| Yes                                          | 12/14 (85.7%)      |         |

**Table 3: Recipient and donor risk factors as predictors of HCV recurrence.**

CMV: Cytomegalovirus; MMF: Mycophenolate mofetil
Recurrent Hepatitis C Virus (Genotype 4) Infection after Living Donor Liver Transplantation: Risk Factors and Outcome. J Liver 3: 148. doi:10.4172/2167-0889.1000148

Table 4: Recipient and donor risk factors as predictors of HCV recurrence.

| Category                        | Recurrence (Mean±Std. deviation) | No recurrence (Mean±Std. deviation) | p-value |
|---------------------------------|----------------------------------|-------------------------------------|---------|
| Recipient age                   | 48.38 ± 4.165                    | 45.15 ± 9.410                       | > 0.05  |
| MELD                            | 17.10 ± 3.520                    | 17.29 ± 3.889                       | > 0.05  |
| Donor Age                       | 26.05 ± 8.115                    | 27.38 ± 8.068                       | > 0.05  |
| BMI of Donor                    | 25.68 ± 3.824                    | 25.17 ± 3.552                       | > 0.05  |
| Calculated graft weight (920 - 1060) | 938.97 ± 168.040               | 938.97 ± 168.040                   | > 0.05  |
| Calculated GRWR                 | 1.1400 ± 0.21984                 | 1.1871 ± 0.24570                   | > 0.05  |
| Actual graft wt                 | 980.48 ± 103.222                 | 844.12 ± 152.139                   | > 0.05  |
| Actual GRWR                     | 1.0905 ± 0.16770                | 1.0721 ± 0.19770                   | > 0.05  |
| Cold ischemia time/ minutes     | 72.14 ± 31.645                   | 67.42 ± 55.637                     | > 0.05  |
| Warm ischemia time/ minutes     | 50.48 ± 15.484                   | 46.03 ± 15.165                     | > 0.05  |
| Operative time/ h               | 12.490 ± 1.8952                  | 10.934 ± 3.0282                    | < 0.05  |
| Blood transfusion/unit          | 5.19 ± 5.046                     | 4.18 ± 5.072                       | > 0.05  |
| Plasma transfusion/ unit        | 7.67 ± 3.398                     | 3.71 ± 4.373                       | < 0.05  |

BMI: Body mass index

9.1%, 8.8% and 9.5% respectively. While overall 1, 3 and 5 year survival of all patients was 94.5%, 90.9% and 90.9% respectively. On the other hand the overall 1, 3 and 5 year’s survival of patients with and without recurrence was 95.2%, 90.5% and 90.5% and 94.1%, 91.2% and 91.2% respectively (Table 6 and Figure 1).

V- On univariate analysis, the following variables were found to be statistically non-significant predictors of survival despite a trend towards survival: Absence of recurrence of HCV (91.2%) and treatment of recurrence (93.8%) (Table 7).

Discussion

The rates and severity of HCV recurrence are highly variable and are probably related to the complex interplay of host factors, iatrogenic influences (e.g., immunosuppressant, antiviral treatment), and possibly genetic variability of the allograft [9]. The incidence of recurrence in our study was 21/55 of patients (38.2%) during the follow up period (6 months to 60 months), while, 1, 3 and 5 years HCV recurrence was (25.4%, 36.3% and 38.2% respectively). Similarly, in the studies by Yosry et al. in 2009 [2], and Raffaella et al. in 2010 [4], HCV recurrence was found in 23/74 (31.1%), and 25/45 (46.2%) respectively. In contrast, in a study by Francisco et al. in 2006 [10], serological recurrence of HCV in their study was 100%, and histological recurrence was 92%, they found that 1-, 3- and 5- years HCV recurrence was (51.5%, 83.5%, and 92% respectively). This is due to recurrent 100% viraemia after graft reperfusion, and high reinfection due to immunosuppression.

While overall survival of all, non-recurrent, and recurrent HCV patients was 90.9%, 91.2% and 90.5% respectively. Similarly, Yosry et al. in 2009 [2], found (91.3%) 3- y HCV survival rate in their recurrent patients. However, in a study by Doris et al. in 2010 [11], HCV survival was (95%); he concluded that the majority of patients with recurrent HCV develop graft dysfunction affecting survival, and leading to cirrhosis. In contrast, in our study, 1 (4.7%) of the recurrent 21 patients developed graft cirrhosis. Furthermore, antiviral treatment in transplant patients is feasible and does not induce severe immunological effects, so, it is recommended in recurrent HCV to use antiviral in the form of PEG plus Ribavirin, with good SVR and survival [6]. In the current study, we found that, survival was better (93.8%) in patients who underwent management of their recurrent HCV than who did not undergo management (80%). Also in a study by Raffaella et al. in 2010 [4], it was found that long term maintenance Ribavirin monotherapy was associated with reduced fibrosis progression in recurrent HCV patients and better survival.

In the recent study, recipient age wasn’t a significant predictor of HCV recurrence. Similarly, in the study by Yosry et al. in 2009 [2], and Doris et al. [11], there was no correlation between recipient age and HCV recurrence. In contrast, in a study by Charlton and Menon...
older recipients, were significantly correlated with more severe recurrence of HCV, perhaps because older patients are less able to mount an effective immune response against viral recurrence [12].

There was a trend towards significant HCV recurrence in the current study regarding male recipients. In contrast, female gender has been associated with a severe course of recurrent hepatitis C, and male recipient was significant predictor of fibrosis progression in recurrent HCV in the studies by Forman et al. in 2002 [13], and Raffaella et al. in 2010 [4] respectively.

It was found that there was no significant correlation between donor age and recurrence in the present study, similarly, in the studies by Yosry et al. in 2009 [2] and Doris et al. in 2010 [11] there were no correlation between donor age and HCV recurrence. In contrast, in the studies by (Berenguer, 2003 [14], Charlton and Menon, 2005 [5], Cameron et al. [12], and Francisco et al. [10] donor age <31 years was significant predictor of HCV recurrence, perhaps because older grafts are less able to mount an effective immune response against viral recurrence [12].

We found no significant correlation between donor gender and HCV recurrence, also, in the study by Yosry et al. [2], there was no correlation between donor gender and HCV recurrence, on the other hand, Cameron et al. in 2006 [2], found that male donors were significant predictors of HCV recurrence.

We studied the correlation between the post-transplant HCV recurrence and both the pretransplant Child-Pugh classification and the Model for End-Stage Liver Disease (MELD) score and found no significant correlation, this result is in consistence with one important recent study in which no significant correlation was found between the pre transplantation severity of liver disease and recurrence of HCV after transplantation, it is the study by Yosry et al. [2], in which pretransplant Child-Pugh classification and the MELD score, were non-significant predictors of HCV recurrence. Co-morbidity is a host factor associated with HCV recurrence [15]. In contrast, it was not a significant predictor of recurrence in the current study despite the higher recurrence rate in patients with Co-morbidity.

Cytomegalovirus (CMV) infection has been strongly associated with increased severity of HCV recur¬rence [5]. Similarly, in the current study there was significant association between CMV infection, and recurrence, inversely, Doris and associates in 2010 [11], concluded that CMV had no impact on HCV recurrence.

The current study did not show any significant correlation between graft size, and GRWR and HCV recurrence, similarly Yosry et al. [2], did not find significant association between the graft volume or between GRWR of <1%, or >1%, and HCV recurrence, despite the larger graft volume(836 ± 142 g) in non-recurrent group in their study.

Immunosuppression is considered a main factor in the severity of recurrent hepatitis C virus infection [16], because of its effect on viral replication and its suppression of the systemic immune responses, both of which can lead to accelerated hepatocellular damage and fibrosis. So, modifying immunosuppression are the main means of preventing disease progression [2]. Doris et al. in 2010 [2], found that patients in the Calcineurin inhibitors group showed a significant trend towards HCV recurrence as compared to patients on SIR therapy during their follow up period. In contrast, in the current study, the regimen of immunosuppression (tacroloimus based, cyclosporine based or sirolimus based), was not significantly associated with disease recurrence. The possible explanation for that finding is that steroids were administered to the study subjects for only 3 months, and monotherapy was the standard immunosuppressive regimen in our center. While, Francisco et al. [10], and Yosry et al. [2], found no significant correlation between the regimen of immunosuppression, and hepatitis C virus recurrence. Also, in the study done by Balbi et al. in 2009 [6], and Jiménez-Pérez et al. in 2010 [17], there was no significant association between tacrolimus based or cyclosporine based immunosuppression and SVR, after treatment for recurrent hepatitis C virus infection after liver transplantation. Francisco and associates in 2006 [10], found significant correlation between MMF, and low HCV recurrence. On the other hand, several authors reported that MMF administration was not associated with low HCV recurrence [18]. Similarly, in the present study we did not show significant correlation between MMF administration, and disease recurrence.

Treatment with steroids for acute cellular rejection episodes has been reported to be a risk factor for the severity of HCV recurrence [19]. In the studies by Francisco et al. in 2006 [10] and Doris et al. in 2010 [11], there was significant correlation between pulse steroids and HCV recurrence. Similarly, we found a high significant association between acute rejection episodes and pulse steroids administration and HCV recurrence in the univariate analysis, this acute rejection and pulse steroids administration was independent predictor of recurrence in the multivariate analysis.

In conclusion, the occurrence of acute rejection was independent predictor of HCV recurrence post LDLT, so its prevention is required to decrease this recurrence. Similarly, prevention of CMV infection and decreasing operative time is important to decrease post-transplant HCV recurrence.

Acknowledgement

Forms of support received by each author for this study included good selection of cases, instructive supervision, continuous guidance, valuable suggestions and good instructions. No grant or other financial support was received for this study.

References

1. Muiesan P, Vergani D, Mieti-Vergani G (2007) Liver transplantation in children. J Hepatol 46: 340-348.
2. Yosry A, Abdel-Rahman M, Esmat G, El-Serafy M, Omar A, et al. (2009) Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplantation in Egyptian patients. Exp Clin Transplant 7: 157-163.
3. Caremmani M, Taccori D, Giorni P, Lapini L, Corradini S, et al. (2007) Clinical management of patients with recurrent viral hepatitis after liver transplantation. J Ultrasound 10: 46-52.
4. Lionetti R, Tisone G, Palmieri G, Almerighi C, Anselmo A, et al. (2010) Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression. Dig Liver Dis 42: 297-303.
5. Chartlon MR, Menon KV (2005) Late complications of liver transplantation and recurrence of disease. In: Ronald WB, Goran KK (Eds.), Transplantation of the liver (2ndedn) 65: 995-1017.
6. Balbi E, Leal CR, Pacheco-Moreira LF, Pousa FS, Coveio MC, et al. (2009) Treatment for recurrent hepatitis C virus infection after liver transplantation. Transplant Proc 41: 891-894.
7. (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French META/IR Cooperative Study Group. Hepatology 20: 15-20.
8. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
9. Rosen HR (2000) Disease recurrence following liver transplantation. Clin Liver Dis 4: 675-689.
10. Sánchez-Bueno F, Ortiz ML, Bermejo J, Miras M, Pons JA, et al. (2006)
Prognostic factors for HCV recurrence in patients undergoing liver transplantation. Transpl Immunol. 17: 47-50.

11. Doris W, Daniela K, Silvia S, Estrella J, Helmut M, et al. (2010) Sirolimus has a potential to influence viral recurrence in HCV positive liver transplant candidates. International Immunopharmacology 20: 200-207.

12. Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, et al. (2006) Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 244: 563-571.

13. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR (2002) The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122: 869-896.

14. Berenguer M (2003) Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 9: S44-47.

15. Berenguer M, López-Labrador FX, Wright TL (2001) Hepatitis C and liver transplantation. J Hepatol 35: 666-678.

16. Charlton M (2003) Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 9: S58-62.

17. Jiménez-Pérez M, Sáez-Gómez AB, Pérez-Daga JA, Lozano-Rey JM, de la Cruz-Lombardo J, et al. (2010) Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response. Transplant Proc 42: 666-668.

18. Firpi RJ, Nelson DR, Davis GL (2003) Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 9: 57-61.

19. Ciccorossi P, Maina AM, Oliveri F, Petruccelli S, Leandro G, et al. (2007) Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int 27: 612-619.